BIOGEN INC. Net Change in Cash
BIOGEN INC. (BIIB) reported Net Change in Cash of $1.14 billion for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-22.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-10-22
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $640.00M, a 43.95% decline year-over-year.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$522.50M.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $1.02B, a 59.80% decline year-over-year.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $1.14B, a 215.53% increase year-over-year.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$792.10M, a 175.45% decline from fiscal 2016.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.05B, a 605.04% increase from fiscal 2015.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $148.90M, a 76.85% decline from fiscal 2014.
- BIOGEN INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $643.20M, a 2591.21% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | $640.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $117.50M derived: sum of 2 quarters · filed 2019-10-22 | $1.14B 10-Q · filed 2019-10-22 | |||||
| 2019-06-30 | -$522.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $496.50M 10-Q · filed 2019-07-24 | ||||||
| 2019-03-31 | $1.02B 10-Q · filed 2019-04-24 | |||||||
| 2018-09-30 | $1.14B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | -$1.70B derived: sum of 2 quarters · filed 2019-10-22 | $836.30M 10-Q · filed 2019-10-22 | $877.00M derived: sum of 4 quarters · filed 2019-10-22 | ||||
| 2018-06-30 | -$2.84B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | -$305.60M 10-Q · filed 2019-07-24 | -$264.90M derived: sum of 3 quarters · filed 2019-07-24 | $97.00M derived: sum of 4 quarters · filed 2019-07-24 | ||||
| 2018-03-31 | $2.54B 10-Q · filed 2019-04-24 | $2.58B derived: sum of 2 quarters · filed 2019-04-24 | $2.94B derived: sum of 3 quarters · filed 2019-04-24 | $3.15B derived: sum of 4 quarters · filed 2019-04-24 | ||||
| 2017-12-31 | $40.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $402.60M derived: sum of 2 quarters · filed 2018-10-23 | $618.30M derived: sum of 3 quarters · filed 2018-10-23 | -$792.10M 10-K · filed 2018-02-01 | ||||
| 2017-09-30 | $361.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $577.60M derived: sum of 2 quarters · filed 2018-10-23 | -$832.80M 10-Q · filed 2018-10-23 | -$559.10M derived: sum of 4 quarters · filed 2018-10-23 | ||||
| 2017-06-30 | $215.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24 | -$1.19B 10-Q · filed 2018-07-24 | -$1.19B 10-Q · filed 2017-07-25 | -$921.00M derived: sum of 3 quarters · filed 2018-07-24 | -$198.80M derived: sum of 4 quarters · filed 2018-07-24 | |||
| 2017-03-31 | -$1.41B 10-Q · filed 2018-04-24 | -$1.14B derived: sum of 2 quarters · filed 2018-04-24 | -$414.50M derived: sum of 3 quarters · filed 2018-04-24 | -$168.20M derived: sum of 4 quarters · filed 2018-04-24 | ||||
| 2016-12-31 | $273.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $995.90M derived: sum of 2 quarters · filed 2018-02-01 | $1.24B derived: sum of 3 quarters · filed 2018-02-01 | $1.05B 10-K · filed 2018-02-01 | ||||
| 2016-09-30 | $722.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $968.50M derived: sum of 2 quarters · filed 2017-10-24 | $776.10M 10-Q · filed 2017-10-24 | -$1.99B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-06-30 | $246.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $53.90M 10-Q · filed 2017-07-25 | -$2.71B derived: sum of 3 quarters · filed 2018-02-01 | $101.40M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-03-31 | -$192.40M 10-Q · filed 2017-04-25 | -$2.96B derived: sum of 2 quarters · filed 2018-02-01 | -$144.90M derived: sum of 3 quarters · filed 2018-02-01 | -$354.50M derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2015-12-31 | -$2.77B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $47.50M derived: sum of 2 quarters · filed 2018-02-01 | -$162.10M derived: sum of 3 quarters · filed 2018-02-01 | $148.90M 10-K · filed 2018-02-01 | ||||
| 2015-09-30 | $2.81B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $2.60B derived: sum of 2 quarters · filed 2016-10-26 | $2.91B 10-Q · filed 2016-10-26 | $2.91B 10-Q · filed 2015-10-21 | $2.96B derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-06-30 | -$209.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $101.40M 10-Q · filed 2016-07-21 | $101.34M 10-Q · filed 2015-07-24 | $142.65M derived: sum of 3 quarters · filed 2017-02-02 | $481.00M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-03-31 | $311.00M 10-Q · filed 2016-04-21 | $311.02M 10-Q · filed 2015-04-24 | $352.25M derived: sum of 2 quarters · filed 2017-02-02 | $690.60M derived: sum of 3 quarters · filed 2017-02-02 | $728.71M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2014-12-31 | $41.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $379.60M derived: sum of 2 quarters · filed 2017-02-02 | $417.71M derived: sum of 3 quarters · filed 2017-02-02 | $643.20M 10-K · filed 2017-02-02 | $643.27M 10-K · filed 2015-02-04 | |||
| 2014-09-30 | $338.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $376.45M derived: sum of 2 quarters · filed 2015-10-21 | $601.95M 10-Q · filed 2015-10-21 | $772.17M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $38.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | $263.60M 10-Q · filed 2015-07-24 | $433.83M derived: sum of 3 quarters · filed 2016-02-03 | $462.84M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $225.49M 10-Q · filed 2015-04-24 | $395.72M derived: sum of 2 quarters · filed 2016-02-03 | $424.73M derived: sum of 3 quarters · filed 2016-02-03 | $152.94M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $170.23M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $199.24M derived: sum of 2 quarters · filed 2016-02-03 | -$72.56M derived: sum of 3 quarters · filed 2016-02-03 | $23.90M 10-K · filed 2016-02-03 | $23.88M 10-K · filed 2014-02-06 | |||
| 2013-09-30 | $29.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | -$242.78M derived: sum of 2 quarters · filed 2014-10-22 | -$146.33M 10-Q · filed 2014-10-22 | -$29.40M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | -$271.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | -$175.34M 10-Q · filed 2014-07-23 | -$58.41M derived: sum of 3 quarters · filed 2015-02-04 | -$67.26M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $96.46M 10-Q · filed 2014-04-23 | $213.38M derived: sum of 2 quarters · filed 2015-02-04 | $204.53M derived: sum of 3 quarters · filed 2015-02-04 | $369.55M derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2012-12-31 | $116.93M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $108.07M derived: sum of 2 quarters · filed 2015-02-04 | $273.10M derived: sum of 3 quarters · filed 2015-02-04 | $52.08M 10-K · filed 2015-02-04 | ||||
| 2012-09-30 | -$8.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $156.17M derived: sum of 2 quarters · filed 2013-10-28 | -$64.85M 10-Q · filed 2013-10-28 | -$123.22M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-06-30 | $165.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$56.00M 10-Q · filed 2013-07-25 | -$114.36M derived: sum of 3 quarters · filed 2014-02-06 | -$230.15M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-03-31 | -$221.02M 10-Q · filed 2013-04-25 | -$279.39M derived: sum of 2 quarters · filed 2014-02-06 | -$395.17M derived: sum of 3 quarters · filed 2014-02-06 | -$490.39M derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2011-12-31 | -$58.37M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | -$174.15M derived: sum of 2 quarters · filed 2014-02-06 | -$269.37M derived: sum of 3 quarters · filed 2014-02-06 | -$242.41M 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | -$115.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | -$211.00M derived: sum of 2 quarters · filed 2012-10-25 | -$184.05M 10-Q · filed 2012-10-25 | -$45.69M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | -$95.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | -$68.27M 10-Q · filed 2012-07-24 | $70.09M derived: sum of 3 quarters · filed 2013-02-05 | -$32.68M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $26.95M 10-Q · filed 2012-05-01 | $165.31M derived: sum of 2 quarters · filed 2013-02-05 | $62.54M derived: sum of 3 quarters · filed 2013-02-05 | $148.86M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | $138.36M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $35.59M derived: sum of 2 quarters · filed 2013-02-05 | $121.91M derived: sum of 3 quarters · filed 2013-02-05 | $185.08M 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | -$102.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | -$16.45M derived: sum of 2 quarters · filed 2011-10-28 | $46.72M 10-Q · filed 2011-10-28 | $41.92M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | $86.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $149.49M 10-Q · filed 2011-07-26 | $144.70M derived: sum of 3 quarters · filed 2012-02-03 | -$57.10M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $63.17M 10-Q · filed 2011-04-21 | $58.38M derived: sum of 2 quarters · filed 2012-02-03 | -$143.42M derived: sum of 3 quarters · filed 2012-02-03 | -$123.23M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2009-12-31 | -$4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$206.59M derived: sum of 2 quarters · filed 2012-02-03 | -$186.40M derived: sum of 3 quarters · filed 2012-02-03 | -$44.28M 10-K · filed 2012-02-03 | ||||
| 2009-09-30 | -$201.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | -$181.60M derived: sum of 2 quarters · filed 2010-10-26 | -$39.49M 10-Q · filed 2010-10-26 | -$429.79M derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2009-06-30 | $20.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $162.30M 10-Q · filed 2010-07-20 | -$228.00M derived: sum of 3 quarters · filed 2011-02-04 | $319.55M derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2009-03-31 | $142.12M 10-Q · filed 2010-04-20 | -$248.19M derived: sum of 2 quarters · filed 2011-02-04 | $299.36M derived: sum of 3 quarters · filed 2011-02-04 | |||||
| 2008-12-31 | -$390.30M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $157.25M derived: sum of 2 quarters · filed 2011-02-04 | -$38.05M 10-K · filed 2011-02-04 | |||||
| 2008-09-30 | $547.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $352.25M 10-Q · filed 2009-10-21 | ||||||
| 2008-06-30 | -$195.30M 10-Q · filed 2009-07-17 | |||||||
| 2007-12-31 | -$1.16M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |